Azeria Therapeutics announces £32.0 million series B financing
- Syncona leads £32.0 million Series B financing of Azeria Therapeutics with a £29.5 million commitment
- Opportunity to address a significant unmet need in oestrogen receptor positive breast cancer patients in lead programme and to build a world class pioneer factor oncology company
London, 21 November 2019 – Azeria Therapeutics (Azeria), a newly formed pioneer factor drug discovery company, today announced a £32 million Series B financing in which Syncona has committed £29.5 million alongside existing investor the CRT Pioneer Fund.
